Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA.
Metzenmacher M, Zaun G, Trajkovic-Arsic M, Cheung P, Reissig TM, Schürmann H, von Neuhoff N, O'Kane G, Ramotar S, Dodd A, Gallinger S, Muckenhuber A, Knox JJ, Kunzmann V, Horn PA, Hoheisel JD, Siveke JT, Lueong SS. Metzenmacher M, et al. Mol Oncol. 2024 Oct 31. doi: 10.1002/1878-0261.13747. Online ahead of print. Mol Oncol. 2024. PMID: 39478658 Free article.
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.
Wiesweg M, Küter C, Schnorbach J, Keyl J, Metzenmacher M, Cvetkovic J, Saalfeld FC, Glanemann F, Eberhardt W, Oezkan F, Theegarten D, Stenzinger A, Darwiche K, Koschel D, Herth F, Bölükbas S, Winter H, Weykamp F, Wermke M, Stuschke M, Plönes T, Thomas M, Schuler M, Christopoulos P. Wiesweg M, et al. Among authors: metzenmacher m. Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35199. Online ahead of print. Int J Cancer. 2024. PMID: 39319506
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with immunohistochemistry and survival.
Mavroeidi IA, Romanowicz A, Haake T, Wienker J, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Opitz M, Nader M, Hamacher R, Siveke J, Winantea J, Fendler WP, Wiesweg M, Eberhardt WEE, Herrmann K, Theegarten D, Schuler M, Hautzel H, Kersting D. Mavroeidi IA, et al. Among authors: metzenmacher m. Theranostics. 2024 Aug 26;14(14):5400-5412. doi: 10.7150/thno.98819. eCollection 2024. Theranostics. 2024. PMID: 39310095 Free PMC article.
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).
Schulte C, Gauler T, Pöttgen C, Friedel G, Kopp HG, Fischer B, Schmidberger H, Kimmich M, Budach W, Cordes S, Wienker J, Metzenmacher M, de Los Rios RH, Spengler W, De Ruysscher D, Belka C, Welter S, Luetke-Brintrup D, Guberina M, Oezkan F, Darwiche K, Schuler M, Jöckel KH, Aigner C, Stamatis G, Stuschke M, Eberhardt WEE. Schulte C, et al. Among authors: metzenmacher m. Int J Cancer. 2025 Jan 1;156(1):154-163. doi: 10.1002/ijc.35131. Epub 2024 Aug 28. Int J Cancer. 2025. PMID: 39198970 Clinical Trial.
PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors.
Abu Sabbah T, Theurer S, Baba HA, Lueong S, Rashidi-Alavijeh J, Hilser T, Zaun Y, Metzenmacher M, Pogorzelski M, Virchow I, Pretzell I, Kostbade K, Treckmann J, Wiesweg M, Schuler M, Kasper S, Zaun G. Abu Sabbah T, et al. Among authors: metzenmacher m. Eur J Cancer. 2024 Oct;210:114268. doi: 10.1016/j.ejca.2024.114268. Epub 2024 Aug 10. Eur J Cancer. 2024. PMID: 39153343 Free article.
Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, Schaarschmidt B, Wiesweg M, Aigner C, Plönes T, Darwiche K, Bölükbas S, Stuschke M, Umutlu L, Nader M, Theegarten D, Hamacher R, Eberhardt WEE, Schuler M, Herrmann K, Fendler WP, Hautzel H. Kessler L, et al. Among authors: metzenmacher m. J Nucl Med. 2024 Aug 1;65(8):1188-1193. doi: 10.2967/jnumed.124.267473. J Nucl Med. 2024. PMID: 38960716
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.
Richlitzki C, Wiesweg M, Metzenmacher M, Guberina N, Pöttgen C, Hautzel H, Eberhardt WEE, Darwiche K, Theegarten D, Aigner C, Bölükbas S, Schuler M, Stuschke M, Guberina M. Richlitzki C, et al. Among authors: metzenmacher m. Sci Rep. 2024 Jun 14;14(1):13765. doi: 10.1038/s41598-024-64302-2. Sci Rep. 2024. PMID: 38877146 Free PMC article.
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group. Griesinger F, et al. JTO Clin Res Rep. 2023 Dec 25;5(4):100626. doi: 10.1016/j.jtocrr.2023.100626. eCollection 2024 Apr. JTO Clin Res Rep. 2023. PMID: 38586301 Free PMC article.
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance.
Schuler M, Hense J, Darwiche K, Michels S, Hautzel H, Kobe C, Lueong S, Metzenmacher M, Herold T, Zaun G, Laue K, Drzezga A, Theegarten D, Nensa F, Wolf J, Herrmann K, Wiesweg M. Schuler M, et al. Among authors: metzenmacher m. J Nucl Med. 2024 Jun 3;65(6):851-855. doi: 10.2967/jnumed.123.266979. J Nucl Med. 2024. PMID: 38575188 Clinical Trial.
51 results